Camelid Single-Domain Antibodies: Promises and Challenges as Lifesaving Treatments

Since the discovery of camelid heavy-chain antibodies in 1993, there has been tremendous excitement for these antibody domains (VHHs/sdAbs/nanobodies) as research tools, diagnostics, and therapeutics. Commercially, several patents were granted to pioneering research groups in Belgium and the Netherl...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
1. Verfasser: Mehdi Arbabi-Ghahroudi
Format: Artigo
Sprache:Inglês
Veröffentlicht: MDPI AG 2022-04-01
Schriftenreihe:International Journal of Molecular Sciences
Schlagworte:
camelid heavy-chain antibody
VHH
single-domain antibody
nanobody
caplacizumab
biotherapeutics
Online Zugang:https://www.mdpi.com/1422-0067/23/9/5009
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge